Delhi High Court allows Zydus to sell cheaper cancer drug Nivolumab biosimilar

• Delhi High Court permits Zydus Lifesciences to sell a biosimilar of Bristol Myers Squibb's cancer drug Nivolumab.
• Zydus's biosimilar is priced nearly 70 percent lower, significantly improving affordability and access.
• A division bench overturned an earlier ruling that had restrained Zydus, citing public interest for life-saving drugs.
• The court balanced public health with innovator's rights, directing Zydus to maintain sales records until patent expiry.
• BMS's patent on Nivolumab (Opdiva) is set to expire on May 2, 2026, just four months after this ruling.

Why It Matters: Delhi High Court prioritizes public access to affordable life-saving cancer drugs, balancing innovation and affordability.